Aehr Test Systems (NASDAQ: AEHR) received a record $41 million production order from its lead hyperscale AI customer for package-level burn-in of custom AI processor ASICs. This order pushes Aehr's second-half bookings past $92 million, significantly exceeding prior expectations of $60-$80 million. Deliveries for this order are expected to begin in fiscal 2027, starting June 27, 2026, and the company has also expanded its manufacturing capacity to support this growing demand.

Aehr Test Systems announced a record $41 million follow-on production order from its lead hyperscale customer for package-level burn-in of custom AI processor ASICs, bringing its second-half fiscal year bookings to over $92 million. This order validates the Sonoma platform for high-volume burn-in of AI processor ASICs, and the company projects further demand as customers develop higher-power AI accelerators. Aehr has also expanded its production capacity to meet growing demand across various markets including AI, silicon photonics, and silicon carbide.

Woori Financial Group is considering the integration of Tongyang Life Insurance Co., Ltd. and ABL Life Insurance Co., Ltd., potentially making Tongyang Life Insurance a wholly owned subsidiary. These moves aim to strengthen Woori's competitiveness in the insurance sector, though no final decisions have been made. The company has committed to providing further updates within three months.

Abbott marginally beat Wall Street's first-quarter profit and revenue estimates, driven by its new cancer diagnostics business and strong medical device unit performance. Despite this, the company's shares fell 2% after it announced a 20-cent hit to its 2026 profit forecast due to the $23 billion acquisition of Exact Sciences. CEO Robert Ford stated that the acquisition still adds a high-growth business to Abbott's portfolio.

Abbott announced its first-quarter 2026 financial results, with sales increasing 7.8 percent on a reported basis and 3.7 percent on a comparable basis, and adjusted diluted EPS of $1.15. The company also updated its full-year 2026 guidance to reflect the recent acquisition of Exact Sciences, projecting comparable sales growth of 6.5% to 7.5% and adjusted diluted EPS of $5.38 to $5.58. This acquisition establishes Abbott as a leader in the oncology diagnostics market, further strengthening its growth prospects.

BMO Capital analyst Michael Zaremski has increased the price target for Progressive Corp. (PGR) to $221. This article is a premium-only piece, requiring a subscription to StreetInsider.com to read the full details. The update was made on April 16, 2026.

Aligos Therapeutics has announced an exclusive license agreement with Xiamen Amoytop Biotech Co., Ltd. for the development and commercialization of pevifoscorvir sodium in Greater China to treat chronic hepatitis B virus infection. Aligos will receive an upfront payment of $25 million USD and is eligible for up to $420 million USD in milestones, plus tiered royalties. This partnership leverages Amoytop's strong presence in the Chinese hepatology market, aiming to accelerate the development and regulatory success of pevifoscorvir sodium in a region with over 90 million people living with HBV.

Antero Midstream Corporation (NYSE:AM) has announced a quarterly dividend of $0.225 per share, payable on May 13th to shareholders of record on April 29th. The dividend yields approximately 4.2% annually, though its coverage is noted as potentially at risk with an 81.8% payout ratio and a recent EPS miss. Despite insider selling, institutional investors hold a significant portion of the company's stock.

Ally Financial Inc. announced a quarterly dividend of $0.30 per share, payable on May 15th to shareholders of record on May 1st. This dividend represents an annualized yield of 2.8% and is well-covered by earnings, with a payout ratio of 22.1%. The company recently exceeded Q4 earnings estimates and analysts maintain a "Moderate Buy" rating with an average price target of $53.29.

CNBC's 'Final Trades' segment highlighted several stocks, with analysts making recommendations. Netflix (NFLX) was chosen ahead of its Q1 earnings report, while Zoom Communications (ZM) and Apollo Global Management (APO) also received endorsements. Additionally, Invesco QQQ Trust (QQQ) was mentioned as a final trade.